Accessibility Menu
Biomind Labs logo

Biomind Labs(OTC) BMNDF

Market Cap$19.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+0%
5 Year-83%
1 Year+1,484%
1 Month+401%
$0.25
-41.79%
-0.18Today
Biomind Labs last closing stock price
MetricPriceDate
Last closeUSD 0.252026-08-24
Biomind Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-58.28%USD 0.602026-08-17
1 month+400.6%USD 0.052026-07-24
3 month+108.58%USD 0.122026-05-26
Year to date+119.56%USD 0.112025-12-30
1 year+1,484.18%USD 0.022025-08-14
3 year-51.87%USD 0.522023-08-22
5 year-82.5%USD 1.432021-08-16
Since inception+0.12%USD 0.252021-07-27

Biomind Labs Financials at a Glance

Market Cap

$19.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.46M

EPS (TTM)

-$0.02

P/E Ratio

-13.39

Dividend

$0.00

Beta (Volatility)

0.21 (Low)

Price

$0.25

Volume

32

Open

$0.25

Previous Close

$0.25

Daily Range

$0.25 - $0.25

52-Week Range

$0.01 - $0.80

Estimated Earnings Date

N/A

BMNDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biomind Labs

Biomind Labs Inc. is a biotechnology firm focused on developing innovative pharmaceutical therapies and advanced nanotech drug delivery systems. The company primarily targets psychiatric and neurological disorders, with several promising candidates in its pipeline.

Products and Services
  • BMND01: Phase II clinical trials for depression treatment
  • BMND08: Phase II trials for anxiety and cognitive decline in Alzheimer's patients
  • Additional candidates for fibromyalgia, substance use disorders, and persistent pain management
Growth Outlook
  • Strong pipeline with multiple candidates in Phase II trials
  • Focus on addressing unmet needs in mental health and neurological disorders
  • Potential for significant market impact as therapies progress
Financial Highlights
  • Recent quarterly net income of -$682,487, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Market capitalization of approximately $19.4 million, suggesting growth potential
Biomind Labs Inc. operates in a rapidly evolving biotechnology sector, with a commitment to addressing critical health challenges. The company's focus on innovative therapies positions it well for future growth, particularly as it advances its clinical trials. Despite current financial challenges, the potential for breakthrough treatments in mental health and neurological disorders could attract significant interest from investors. The ongoing development of its product pipeline, combined with a strategic approach to addressing unmet medical needs, underscores the company's long-term vision and growth potential.
AI Generated • Aug 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3

CEO

Alejandro Antalich

Website

biomindlabs.com

Headquarters

Vancouver, BC V7Y 1C6, CA

BMNDF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

83.30%

Return on Capital

N/A

Return on Assets

-4170814.29%

Earnings Yield

-7.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.57M

Volume

32

Avg. Volume

3.89K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.38M

EBITDA

-$1.38M

Operating Cash Flow

-$232.89K

Capital Expenditure

-$3.00

Free Cash Flow

-$232.89K

Cash & ST Invst.

$35.00

Total Debt

$828.72K

Biomind Labs Performance Analysis

Biomind Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Biomind Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Biomind Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.04-33.6%
20232023-12-31USD -0.02-60.2%
20242024-12-31USD -0.00-78.6%
20252025-12-31USD -0.01223.5%
Biomind Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.3%
Q42025-12-31-469.2%
Q12026-03-3182.4%
Q22026-06-30-576.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$19.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.88M

N/A

Employees

5

N/A

Net Income

-$682.49K

-485.6%

EBITDA

-$655.81K

-566.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$35.00

-87.3%

Total Debt

$828.72K

+27.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$828.72K

+27.9%

Return on Assets

-41708.14%

N/A

Return on Invested Capital

72.65%

N/A

Free Cash Flow

-$79.04K

-502.1%

Operating Cash Flow

-$79.04K

-502.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ISCOInternational Stem Cell Corporation
$0.42+0.00%
ENZCEnzolytics Inc.
$0.00+0.00%
VCNXVaccinex, Inc.
$0.75+0.00%
EVFMEvofem Biosciences, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About BMNDF

What is the current price of Biomind Labs?

Biomind Labs is trading at $0.25 per share.

What is the 52-week range for Biomind Labs?

Over the past 52 weeks, Biomind Labs has traded between $0.01 and $0.80.

How much debt does Biomind Labs have?

As of the most recent reporting period, Biomind Labs reported total debt of $828.72K.

How much cash does Biomind Labs have on hand?

Biomind Labs reported $35.00 in cash and cash equivalents in its most recent financial results.

What is Biomind Labs’s dividend yield?

Biomind Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services